stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Return on equity
Celldex Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −43.9%, down 3.3 percentage points from fiscal 2025 (−40.6%). Over the past ten years it has ranged from −83.9% (fiscal 2018) to −22.4% (fiscal 2021); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −40.6% | (13.78) |
| FY2024 | −26.8% | 10.61 |
| FY2023 | −37.5% | (7.32) |
| FY2022 | −30.1% | (7.70) |
| FY2021 | −22.4% | 16.98 |
| FY2020 | −39.4% | 7.25 |
| FY2019 | −46.7% | 37.23 |
| FY2018 | −83.9% | (46.81) |
| FY2017 | −37.1% | 9.19 |
| FY2016 | −46.3% | 4.43 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| ADMA ADMA Biologics Inc compare | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| CLDX Celldex Therapeutics, Inc. | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| IMNM Immunome, Inc. compare | −64.0% |
| PHVS Pharvaris N.V. compare | −71.5% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement